NewLink Genetics Corporation (NASDAQ:NLNK) Getting Somewhat Favorable Press Coverage, Study Finds

News stories about NewLink Genetics Corporation (NASDAQ:NLNK) have been trending somewhat positive on Monday, Accern reports. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. NewLink Genetics Corporation earned a news impact score of 0.18 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 47.2476292595661 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Here are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:

Shares of NewLink Genetics Corporation (NASDAQ:NLNK) opened at 6.42 on Monday. The firm’s 50-day moving average price is $7.28 and its 200-day moving average price is $13.58. NewLink Genetics Corporation has a 12-month low of $5.90 and a 12-month high of $25.17. The stock’s market cap is $188.88 million.

NewLink Genetics Corporation (NASDAQ:NLNK) last posted its quarterly earnings results on Friday, July 28th. The biotechnology company reported ($0.57) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.78) by $0.21. The business had revenue of $10.37 million during the quarter, compared to the consensus estimate of $2.65 million. NewLink Genetics Corporation had a negative net margin of 161.94% and a negative return on equity of 55.03%. On average, analysts forecast that NewLink Genetics Corporation will post ($2.82) EPS for the current fiscal year.

Several research analysts recently issued reports on NLNK shares. Cantor Fitzgerald set a $32.00 price objective on NewLink Genetics Corporation and gave the stock a “buy” rating in a research note on Thursday, May 4th. Jefferies Group LLC reissued a “hold” rating and issued a $18.00 price objective on shares of NewLink Genetics Corporation in a research note on Monday, May 15th. Stifel Nicolaus reissued a “buy” rating and issued a $26.00 price objective on shares of NewLink Genetics Corporation in a research note on Saturday, April 22nd. Zacks Investment Research cut NewLink Genetics Corporation from a “hold” rating to a “sell” rating in a research note on Wednesday, July 12th. Finally, ValuEngine raised NewLink Genetics Corporation from a “sell” rating to a “hold” rating in a research note on Friday, May 19th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $18.17.

COPYRIGHT VIOLATION NOTICE: This story was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at

About NewLink Genetics Corporation

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Insider Buying and Selling by Quarter for NewLink Genetics Corporation (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply